<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02840526</url>
  </required_header>
  <id_info>
    <org_study_id>SUM-PSK-1</org_study_id>
    <nct_id>NCT02840526</nct_id>
  </id_info>
  <brief_title>Thoracic Paravertebral Block in Pain Management After Renal Surgery</brief_title>
  <official_title>Thoracic Paravertebral Block in Postoperative Pain Management After Renal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Silesian University of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Silesian University of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: The objective of the study was to assess the usefulness of ThPVB in postoperative
      pain management after open renal resection surgery.

      Design, setting, participants: It was a prospective, randomised, open label study held in a
      university hospital between 08.2013-12.2014. 58 Patients enrolled in the study were scheduled
      for elective open renal surgery (open nephrectomy or open nephron-sparing surgery) and
      randomised into two groups - group PVB (n=27) and group GEN (n=31).

      Interventions: PVB group received preoperative ThPVB with 0,5% bupivacaine followed by
      general anaesthesia. GEN group received standard general anaesthesia. Both groups were
      treated postoperatively with oxycodone IV PCA (patient controlled analgesia) combined with
      non-opioid analgesics as rescue drugs. The investigators recorded pain severity in VAS,
      oxycodone requirement in time points, total oxycodone requirement, and sedation levels
      throughout the first 48h. The investigators measured opioid related adverse events 24 and 48
      h postoperatively and patients satisfaction 48h postoperatively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In PVB group before the induction of general anaesthesia a single shot thoracic paravertebral
      blockade was performed. ThPVB was performed on Th7-Th10 level, approximately 2,5 - 3 cm
      lateral from the top of the spinous process with prior ultrasound control of the depth of the
      transverse process and the pleura. To make the procedure safer the investigators used
      peripheral nerve stimulation with an isolated 10 cm needle with a start current of 2,5 mA.
      The needle was inserted until visible muscle activity from intercostal muscles appeared, with
      a current of 0,5-0,3mA (paravertebral space identification). Next 0,3 ml kg-1 0,5% plain
      bupivacaine was injected after negative aspiration for air and blood. The efficacy of the
      blockade was checked after 20 minutes with cold saline.

      In both groups, PVB and GEN general anaesthesia was induced with midazolam 0,1 mgkg-1,
      propofol 2 mgkg-1, cis-atracurium 0,15 mgkg-1 and fentanyl 1,5 µgkg-1. Patients were
      intubated with a standard single lumen tracheal tube. Anaesthesia was maintained with 1 MAC
      (Minimal Alveolar Concentration) sevoflurane. For surgical analgesia the investigators used
      fractional doses of fentanyl 1-3 mg kg-1 if HR (heart rate) or MBP (mean blood pressure)
      raised above 20% of basal values. Waking up from anaesthesia was in a post-anaesthesia care
      unit.

      Postoperative pain management schedule was identical in both groups. After the surgery, if
      pain appeared, the patient was given oxycodone i.v. titrated to achieve acceptable analgesia
      level or until side effects appeared. Every patient received a PCA (Patient controlled
      analgesia) device with a 1 mgml-1 concentration oxycodone solution with a programmed single
      bolus dose of 1 mg and a lockout time of 5 minutes. Additionally, patients were given 1g i.v.
      paracetamol every 6 hours and 100 mg of i.v. ketoprofen every 12 hours.

      For 48 h postoperatively, the investigators monitored HR, SBP (systolic blood pressure) , DBP
      (diastolic blood pressure), sedation level in Ramsay scale, pain intensity at rest in VAS
      (visual analogue score) scale, oxycodone requirement in pre-selected time points and total
      oxycodone requirement. The investigators also recorded opioid-related adverse events 24 and
      48 h postoperatively in OBAS scale and patients' satisfaction regarding postoperative
      analgesia 48 h postoperatively in Likert scale.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in total amount of oxycodone needed in 48 hours after surgery</measure>
    <time_frame>48 hours postoperatively</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in prevalence of opioid related adverse events in OBAS scale</measure>
    <time_frame>24 hours, 48 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in pain level in VAS scale</measure>
    <time_frame>48 hours postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in level of sedation assessed in Ramsay scale</measure>
    <time_frame>48 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in patient satisfaction level assessed in Likert scale</measure>
    <time_frame>48 hours after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>PVB group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thoracic paravertebral blockade PVB (preoperatively) Bupivacaine WZF Sopodorm Propofol WZF Fentanyl WZF Nimbex Sevorane Intubation Oxynorm Ketonal Paracetamol Kabi</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GEN group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sopodorm Propofol WZF Fentanyl WZF Nimbex Sevorane Intubation Oxynorm Ketonal Paracetamol Kabi</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Paravertebral blockade (PVB)</intervention_name>
    <description>preoperative ThPVB performed unilaterally at Th10 level</description>
    <arm_group_label>PVB group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sopodorm</intervention_name>
    <description>midazolam 0,1 mgkg-1 intravenously (anesthesia induction)</description>
    <arm_group_label>PVB group</arm_group_label>
    <arm_group_label>GEN group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol WZF</intervention_name>
    <description>propofol 2 mgkg-1intravenously (anesthesia induction)</description>
    <arm_group_label>PVB group</arm_group_label>
    <arm_group_label>GEN group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimbex</intervention_name>
    <description>cis-atracurium 0,15 mgkg-1 intravenously (anesthesia induction)</description>
    <arm_group_label>PVB group</arm_group_label>
    <arm_group_label>GEN group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl WZF</intervention_name>
    <description>fentanyl 1,5 µgkg-1 intravenously (anesthesia induction)</description>
    <arm_group_label>PVB group</arm_group_label>
    <arm_group_label>GEN group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevorane</intervention_name>
    <description>sevoflurane in 1 MAC (Minimal Alveolar Concentration) - anesthesia maintenance</description>
    <arm_group_label>PVB group</arm_group_label>
    <arm_group_label>GEN group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intubation</intervention_name>
    <description>Intratracheal intubation with a single lumen endotracheal tube</description>
    <arm_group_label>PVB group</arm_group_label>
    <arm_group_label>GEN group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxynorm</intervention_name>
    <description>1 mgml-1 concentration oxycodone solution intravenously</description>
    <arm_group_label>PVB group</arm_group_label>
    <arm_group_label>GEN group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol Kabi</intervention_name>
    <description>1g paracetamol intravenously every 6 hours</description>
    <arm_group_label>PVB group</arm_group_label>
    <arm_group_label>GEN group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketonal</intervention_name>
    <description>100 mg ketoprofen intravenously every 12 hours</description>
    <arm_group_label>PVB group</arm_group_label>
    <arm_group_label>GEN group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine WZF</intervention_name>
    <description>0,3 ml kg-1 0,5% plain bupivacaine (regional anesthesia - paravertebral blockade)</description>
    <arm_group_label>PVB group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age 18-75

          -  Scheduled for elective open nephrectomy or NSS

          -  Gave written consent

          -  BMI 19-30

          -  ASA status I-III

        Exclusion criteria:

          -  Presence of chronic pain

          -  Chronic mental conditions (depression)

          -  Contraindications for PVB

          -  Chest or spine deformations

          -  Infection in planned site of PVB

          -  Allergies for drugs used in the study

          -  Cancer invading chest wall
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanna Misiolek, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical School of Silesia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr 1 SUM Zabrze</name>
      <address>
        <city>Zabrze</city>
        <state>Slaskie</state>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2013</study_first_submitted>
  <study_first_submitted_qc>July 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2016</study_first_posted>
  <last_update_submitted>July 18, 2016</last_update_submitted>
  <last_update_submitted_qc>July 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Silesian University of Medicine</investigator_affiliation>
    <investigator_full_name>Maja Copik</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>PVB</keyword>
  <keyword>PCA</keyword>
  <keyword>nephrectomy</keyword>
  <keyword>postoperative pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Cisatracurium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

